43 search results for: disease progression
Impact of Delayed EoE Diagnosis on Disease Progression and QoL
Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.
Low Disease Activity and Disease Stability: Setting New Goals for COPD Care
This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.
UEGW 2024 | WHY Is Long-Term Management of EoE Important?
Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.
Gap in Care Leads to Progression of Fibrosis in EoE
Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.
Uncovering the Impact of Moderate COPD Exacerbations
Understand the impact of moderate chronic obstructive pulmonary disease (COPD) exacerbations on future exacerbation risk, lung function decline, mortality, and patient quality of life.
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.
Managing the Risk of Fibrostenosis in EoE
Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
Can early intervention modify the course of AD?
Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.
Importance of Assessing Multiple Disease Domains in EoE
Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.
Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care
Join leading experts in EoE, Thomas Greuter, MD, Edoardo Vincenzo Savarino, MD, PhD, and Carla Giordano, MD, PhD, as they use a case-based approach to explore the impact of chronic type 2 inflammation in EoE and outline strategies for optimizing transition of care and monitoring disease progression. They review the latest clinical evidence on therapeutic management and share insights from their own practice to support shared decision-making in the long-term care of EoE.
